(Q51022571)

27 March 2018

title

Incidence of serious respiratory infections in patients with rheumatoid arthritis treated with tocilizumab. (English)

1 reference

27 March 2018

1 reference

1 reference

15

Hisashi Yamanaka

1 reference

27 March 2018

author name string

Daisuke Hoshi

1

1 reference

27 March 2018

Ayako Nakajima

2

1 reference

27 March 2018

Eisuke Inoue

3

1 reference

27 March 2018

Kumi Shidara

4

1 reference

27 March 2018

Eri Sato

5

1 reference

27 March 2018

Mariko Kitahama

6

1 reference

27 March 2018

Yohei Seto

7

1 reference

27 March 2018

Eiichi Tanaka

8

1 reference

27 March 2018

Wako Urano

9

1 reference

27 March 2018

Naomi Ichikawa

10

1 reference

27 March 2018

Yumi Koseki

11

1 reference

27 March 2018

Shigeki Momohara

12

1 reference

27 March 2018

Astuo Taniguchi

13

1 reference

27 March 2018

Norihiro Nishimoto

14

1 reference

27 March 2018

publication date

8 July 2011

1 reference

27 March 2018

published in

Modern Rheumatology

1 reference

27 March 2018

volume

22

1 reference

27 March 2018

issue

1

1 reference

27 March 2018

page(s)

122-127

1 reference

27 March 2018

Life expectancies of Japanese patients with rheumatoid arthritis: a review of deaths over a 20-year period

cites work

1 reference

https://api.crossref.org/works/10.3109%2FS10165-011-0488-6

Mortality and cause of death in Japanese patients with rheumatoid arthritis based on a large observational cohort, IORRA.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-011-0488-6

Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-011-0488-6

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-011-0488-6

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-011-0488-6

Postmarketing surveillance of the safety and effectiveness of etanercept in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-011-0488-6

Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-011-0488-6

Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibi

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-011-0488-6

Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-011-0488-6

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-011-0488-6

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-011-0488-6

Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-011-0488-6

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-011-0488-6

Increased risk of tuberculosis in patients with rheumatoid arthritis in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-011-0488-6

Efficient management of rheumatoid arthritis significantly reduces long-term functional disability.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-011-0488-6

Validation of a Japanese version of the Stanford Health Assessment Questionnaire in 3,763 patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-011-0488-6

Is there an association between anti-TNF monoclonal antibody therapy in rheumatoid arthritis and risk of malignancy and serious infection? Commentary on the meta-analysis by Bongartz et al

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-011-0488-6

Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-011-0488-6

Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-011-0488-6

Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-011-0488-6

Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor α antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-011-0488-6

10.3109/S10165-011-0488-6

21 January 2018

Identifiers

DOI

1 reference

27 March 2018

release_yvpwneh7jfbefe3cd5q76cncby

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/yvpwneh7jfbefe3cd5q76cncby

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

27 March 2018